KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) EBT: 2010-2025

Historic EBT for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to $57.6 million.

  • Emergent BioSolutions' EBT fell 59.55% to $57.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.9 million, marking a year-over-year increase of 162.37%. This contributed to the annual value of -$142.9 million for FY2024, which is 80.46% up from last year.
  • Per Emergent BioSolutions' latest filing, its EBT stood at $57.6 million for Q3 2025, which was up 442.86% from -$16.8 million recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' EBT peaked at $256.3 million during Q4 2021, and registered a low of -$269.8 million during Q2 2024.
  • For the 3-year period, Emergent BioSolutions' EBT averaged around -$67.3 million, with its median value being -$27.6 million (2024).
  • Per our database at Business Quant, Emergent BioSolutions' EBT crashed by 4,126.32% in 2023 and then soared by 666.12% in 2025.
  • Emergent BioSolutions' EBT (Quarterly) stood at $256.3 million in 2021, then tumbled by 123.96% to -$61.4 million in 2022, then climbed by 11.24% to -$54.5 million in 2023, then spiked by 49.36% to -$27.6 million in 2024, then crashed by 59.55% to $57.6 million in 2025.
  • Its last three reported values are $57.6 million in Q3 2025, -$16.8 million for Q2 2025, and $92.7 million during Q1 2025.